Decitabine
- PDF / 151,255 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 104 Downloads / 165 Views
1 S
Decitabine Myelosuppression: case report
A 77-year-old woman developed myelosuppression during treatment with decitabine for acute myeloid leukaemia (AML). Th woman was diagnosed with AML (M4b) with complex karyotype after admission. One year prior to this admission, she had undergone cardiac pacemaker insertion for sick sinus syndrome. Pre-chemotherapy evaluation showed decreased left ventricular ejection fraction and left ventricular enlargement. Owing to poor cardiac function and financial condition, she started receiving IV decitabine at a reduced dose of 25mg daily (15.9 mg/m2) from day 1–5. Her platelet count was found to be decreased on day 11 and the WBC count was found to be decreased on day 22, indicating myelosuppression. During the period of marrow suppression, she developed urinary system infection, respiratory system infection and haemorrhage of the mucous membrane and skin. The myelosuppression-associated complications were finally controlled through the use of antibiotics (meropenem and micafungin), blood transfusion (neutrophils, platelets, red blood cells) and unspecified haematopoietic growth factors. At day 33, the blood cell count recovered. After one course of decitabine, she achieved a complete cytogenetic response. Her cardiac function did not worsen during or after the decitabine therapy. Sun Y, et al. Dose-reduced decitabine might bring benefits for elderly AML patients with complex karyotype: A case report. Clinical Laboratory: Journal for Clinical Laboratories and Laboratories Related to Blood Transfusion 66: 1415-1418, No. 7, 2020. Available from: URL: http://doi.org/10.7754/Clin.Lab.2020.191224
0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803504471
Reactions 3 Oct 2020 No. 1824
Data Loading...
